Empiric Treatment for Retroperitoneal Abscess
The recommended empiric antimicrobial therapy for retroperitoneal abscess includes broad-spectrum antibiotics that cover gram-negative aerobic and facultative bacilli, enteric gram-positive streptococci, and obligate anaerobic bacilli, with options such as piperacillin-tazobactam, meropenem, imipenem-cilastatin, or doripenem as single agents, or combination therapy with metronidazole plus a third/fourth generation cephalosporin. 1, 2, 3
Initial Management Approach
- Retroperitoneal abscesses >3cm should be managed with radiological percutaneous drainage combined with early empiric administration of antibiotics, which should be adapted based on microbiological culture results 4
- Small abscesses (<3cm) in stable patients can be treated with intravenous antibiotics alone, but require close clinical and biochemical monitoring 4
- Source control through drainage is essential for successful treatment of retroperitoneal abscesses, with percutaneous drainage being the preferred initial approach in most cases 5, 6
Empiric Antibiotic Selection
For Community-Acquired Retroperitoneal Abscess:
Mild-to-moderate severity:
High-risk or severe infection (severe physiologic disturbance, advanced age, immunocompromised):
For Healthcare-Associated Retroperitoneal Abscess:
- Broader coverage is needed with agents active against resistant gram-negative organisms 1
- Recommended regimens include meropenem, imipenem-cilastatin, doripenem, piperacillin-tazobactam, or ceftazidime/cefepime plus metronidazole 1
- Consider adding aminoglycosides or colistin if highly resistant organisms are suspected 1
Special Considerations
- Anti-enterococcal coverage should be included for healthcare-associated infections, particularly in postoperative patients, those who have previously received cephalosporins, immunocompromised patients, or those with valvular heart disease 1
- Empiric antifungal therapy is not recommended unless Candida is isolated from cultures or the patient is critically ill with risk factors for fungal infection 1
- Anti-MRSA coverage (vancomycin) should be added for patients known to be colonized with MRSA or at high risk due to prior treatment failure and significant antibiotic exposure 1
Duration of Therapy and Monitoring
- Antimicrobial therapy should be re-evaluated according to the patient's clinical and biochemical features 4
- Broad-spectrum antimicrobial therapy should be tailored when culture and susceptibility reports become available to reduce the number and spectra of administered agents 1
- Obtain intraperitoneal specimens for culture during drainage procedures to guide targeted antibiotic therapy 7
Surgical Intervention
- Surgery should be considered in cases of percutaneous drainage failure or in patients with signs of septic shock 4
- Surgical intervention is also indicated for patients with enteric fistulae and persistent clinical evidence of sepsis despite initial treatment 4
Common Pitfalls to Avoid
- Avoid ampicillin-sulbactam due to high rates of resistance among community-acquired E. coli 1
- Avoid cefotetan and clindamycin due to increasing prevalence of resistance among the Bacteroides fragilis group 1
- Do not routinely use aminoglycosides for community-acquired infections due to availability of less toxic agents with equivalent efficacy 1
- Be aware that retroperitoneal abscesses may present with insidious symptoms and are often misdiagnosed; maintain a high index of suspicion 8, 9, 10
By following these guidelines for empiric antimicrobial therapy along with appropriate source control measures, the management of retroperitoneal abscesses can be optimized to improve patient outcomes and reduce morbidity and mortality.